10.12 (-%)
As of Nov 20, 2024
Source:
We are a biopharmaceutical company focused on the development, manufacturing and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of pulmonary hypertension (PH). We operate as a single entity through our two wholly owned operating subsidiaries, Liquidia Technologies and Liquidia PAH (formerly known as RareGen).
Country | United States |
Headquarters | morrisville, north carolina |
Phone Number | 919.328.4400 |
Industry | |
CEO | Roger A. Jeffs, Ph.D. |
Website |